

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|                       |  |
|-----------------------|--|
| <b>Name of entity</b> | <b>Proteomics International Laboratories Ltd</b> |
| <b>ABN</b>            | <b>78 169 979 971</b>                            |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                   |
|----------------------------|-------------------|
| <b>Name of Director</b>    | Richard Lipscombe |
| <b>Date of last notice</b> | 6 April 2018      |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |   |
|--|---|
| <b>Direct or indirect interest</b>   | Direct.   |
| <b>Nature of indirect interest (including registered holder)</b><br>Note: Provide details of the circumstances giving rise to the relevant interest. | Not applicable.   |
| <b>Date of change</b>  | 16 April 2018.  |
| <b>No. of securities held prior to change</b>  | <i>Direct</i><br>10,074,614 fully paid ordinary shares ("Shares")<br>75 performance rights<br><br><i>Indirect</i><br>8,936,590 Shares |
| <b>Class</b>   | Performance rights.   |
| <b>Number acquired</b>   | Not applicable.   |
| <b>Number disposed</b>   | 75 performance rights.  |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation  | Not applicable.   |

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

|   |   |
|---|---|
| <b>No. of securities held after change</b>  | <i>Direct</i><br>10,074,614 Shares<br><br><i>Indirect</i><br>8,936,590 Shares |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Lapsed in accordance with the terms and conditions.                           |

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |                 |
|--|-----------------|
| <b>Detail of contract</b>  | Not applicable. |
| <b>Nature of interest</b>  |                 |
| <b>Name of registered holder (if issued securities)</b>  |                 |
| <b>Date of change</b>  |                 |
| <b>No. and class of securities to which interest related prior to change</b><br>Note: Details are only required for a contract in relation to which the interest has changed |                 |
| <b>Interest acquired</b>   |                 |
| <b>Interest disposed</b>   |                 |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and an estimated valuation   |                 |
| <b>Interest after change</b>   |                 |

**Part 3 – +Closed period**

|  |  |
|--|--|
| <b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b> | No. The Company's Trading Policy does not apply to the lapse of performance rights during a Closed Period. |
| <b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>   |  |
| <b>If prior written clearance was provided, on what date was this provided?</b>  |  |

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|                       |  |
|-----------------------|--|
| <b>Name of entity</b> | <b>Proteomics International Laboratories Ltd</b> |
| <b>ABN</b>            | <b>78 169 979 971</b>                            |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |               |
|----------------------------|---------------|
| <b>Name of Director</b>    | John Dunlop   |
| <b>Date of last notice</b> | 23 March 2018 |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |  |
|---|--|
| <b>Direct or indirect interest</b>  | Direct.  |
| <b>Nature of indirect interest (including registered holder)</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | Not applicable.  |
| <b>Date of change</b>   | 16 April 2018  |
| <b>No. of securities held prior to change</b>   | <i>Direct</i><br>3,855,188 fully paid ordinary shares ("Shares")<br>16 performance rights<br><br><i>Indirect</i><br>1,949,000 Shares |
| <b>Class</b>  | Performance rights.  |
| <b>Number acquired</b>  | Nil.   |
| <b>Number disposed</b>  | 16 performance rights.   |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and estimated valuation</small>  | Not applicable.  |

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

|  |  |
|--|--|
| <b>No. of securities held after change</b>   | <i>Direct</i><br>3,855,188 Shares<br><br><i>Indirect</i><br>1,949,000 Shares |
| <b>Nature of change</b><br><small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Lapsed in accordance with the terms and conditions.                          |

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |                 |
|---|-----------------|
| <b>Detail of contract</b>   | Not applicable. |
| <b>Nature of interest</b>   |                 |
| <b>Name of registered holder (if issued securities)</b>   |                 |
| <b>Date of change</b>   |                 |
| <b>No. and class of securities to which interest related prior to change</b><br><small>Note: Details are only required for a contract in relation to which the interest has changed</small> |                 |
| <b>Interest acquired</b>  |                 |
| <b>Interest disposed</b>  |                 |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and an estimated valuation</small>   |                 |
| <b>Interest after change</b>  |                 |

#### Part 3 – +Closed period

|  |  |
|--|--|
| <b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b> | No. The Company's Trading Policy does not apply to the lapse of performance rights during a Closed Period. |
| <b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>   |  |
| <b>If prior written clearance was provided, on what date was this provided?</b>  |  |

---

+ See chapter 19 for defined terms.